HansBiomed Corporation

Equities

A042520

KR7042520007

Medical Equipment, Supplies & Distribution

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
13,490 ^KRW	+7.06%		+2.98%	-8.11%

Feb. 14	HansBiomed Corporation Reports Earnings Results for the First Quarter Ended December 31, 2023	CI
2023	HansBiomed Corporation(KOSDAQ:A042520) added to S&P Global BMI Index	CI

HansBiomed Corporation announced that it expects to receive KRW 20 billion in funding from Osstem Implant Co., Ltd.

December 14, 2020

HansBiomed Corporation (KOSDAQ:A042520) announced a private placement of series 4 non-guaranteed private equity convertible bonds for gross proceeds of KRW 20,000,000,000 on December 15, 2020. The transaction will include participation from Osstem Implant Co., Ltd. (KOSDAQ:A048260). The note carries no interest but yield to maturity at 2.6% annually compounded in every three months.

The bond will mature on December 18, 2023. The bond is convertible into 1,561,524 shares at KRW 12,808 per share. The transaction is expected to close on December 18, 2020.

Latest news about HansBiomed Corporation

HansBiomed Corporation Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 14	CI
HansBiomed Corporation(KOSDAQ:A042520) added to S&P Global BMI Index	23-09-18	CI
HansBiomed Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-15	CI
Tranche Update on HansBiomed Corporation's Equity Buyback Plan announced on June 23, 2022.	22-12-23	CI
Tranche Update on HansBiomed Corporation's Equity Buyback Plan announced on June 23, 2022.	22-12-23	CI
HansBiomed Corporation's Equity Buyback announced on June 23, 2022, has expired with 202,283 shares, representing 2.08% for KRW 1,986.65 million.	22-12-22	CI
Tranche Update on HansBiomed Corporation's Equity Buyback Plan announced on June 23, 2022.	22-09-22	CI
HansBiomed Corporation(KOSDAQ:A042520) dropped from S&P Global BMI Index	22-09-19	CI
Tranche Update on HansBiomed Corporation's Equity Buyback Plan announced on January 17, 2022.	22-07-18	CI
Tranche Update on HansBiomed Corporation's Equity Buyback Plan announced on January 17, 2022.	22-07-18	CI
HansBiomed Corporation's Equity Buyback announced on January 17, 2022, has expired with 246,000 shares, representing 2.46% for KRW 2,962.2 million.	22-07-17	CI
HansBiomed Corporation announces an Equity Buyback for KRW 2,000 million worth of its shares.	22-06-22	CI
HansBiomed Corporation authorizes a Buyback Plan.	22-06-22	CI
Tranche Update on HansBiomed Corporation's Equity Buyback Plan announced on January 17, 2022.	22-04-17	CI
HansBiomed Corporation announces an Equity Buyback for KRW 3,000 million worth of its shares.	22-01-17	CI
HansBiomed Corporation authorizes a Buyback Plan.	22-01-16	CI
HansBiomed Corporation Auditor Raises 'Going Concern' Doubt	21-12-20	CI
HansBiomed Corporation announced that it has received KRW 15 billion in funding from Noh & Partners Corporation	21-10-25	CI
Rebirth Biotechnology Co., Ltd announced that it has received CNY 20 million in funding from HansBiomed Corporation	21-09-23	CI
Rebirth Biotechnology Co., Ltd announced that it expects to receive CNY 20 million in funding from HansBiomed Corporation	21-08-30	CI
HansBiomed Corporation announced that it expects to receive KRW 15 billion in funding from Noh & Partners Corporation	21-08-30	CI
HansBiomed Corporation's Equity Buyback announced on March 20, 2020, has expired.	21-06-18	CI
HansBiomed Corporation announced that it has received KRW 20 billion in funding from Osstem Implant Co., Ltd.	20-12-17	CI
HansBiomed Corporation announced that it expects to receive KRW 20 billion in funding from Osstem Implant Co., Ltd.	20-12-14	CI
HansBiomed Corporation announces an Equity Buyback for 200,000 shares.	20-03-19	CI

Chart HansBiomed Corporation

Duration

Period

More charts

Company Profile

HansBiomed Co.,Ltd is a Korea-based company engaged in the biotechnology industry. The Company mainly provides three categories of products: skin-implant materials, bone-implant materials and silicone products. Its skin-implant materials are used for burn treatment and skin graft under the brand names of SureDerm, BellaGen and GPS. Its bone-implant materials include allogeneic bones, xenogenous bones and synthetic bones used in dentistry, orthopedic and others, which are under the brand names of SureFuse, ExFuse and SureOss. Its silicone products are used for treatments of scars and for breast implant and others, which are under the brand names of BellaGel and Scar Clinic. In addition, it provides hair transplanters and others.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-13 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Medical Devices & Implants

	1st Jan change	Capi.
HANSBIOMED CORPORATION	-8.11%	128M
STRYKER CORPORATION	+8.29%	124B
SMITH & NEPHEW PLC	-5.15%	11.17B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	+4.83%	9.17B
INSPIRE MEDICAL SYSTEMS, INC.	-22.04%	4.71B
AXONICS, INC.	+8.39%	3.44B
ENOVIS CORPORATION	-6.28%	2.88B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-10.23%	2.11B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-5.99%	2.09B
DOUBLE MEDICAL TECHNOLOGY INC.	-22.62%	1.8B

Medical Devices & Implants